AAPGV (Ascentage Pharma) Company Net Income

Official company branding of Ascentage Pharma Group International (AAPGV)

Ascentage Pharma Group is scaling sales of Olverembatinib to capture the global oncology market. The company's bottom-line profit trend demonstrates its financial foundation, with the parameter stabilizing at -0.21. Despite pressure from US patent law and geopolitics, steady cash flow from resistant leukemia therapies provides the portfolio with excellent commercial momentum.

AAPGV (Ascentage) Net Income history from 01/25/2025 to 10/30/2026

Comprehensive metric breakdowns and analytics for Ascentage Pharma (AAPGV)

- price and consensus price forecast:
Stock Quotes Ascentage|AAPGV - Analyst Consensus Forecast
- business market valuation indicators:
Market Value Ascentage|AAPGV - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Ascentage Pharma|AAPGV - Company Net Assets|Market Value to Book Value ascentage.com|AAPGV - Company Total Assets
- debt and liquidity details:
Total Debt to Equity Ratio Ascentage Pharma Group|AAPGV - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Ascentage Pharma Group International|AAPGV - Company Debts|Debt to Net Assets Ratio Ascentage|AAPGV - Company Long-Term Debts|Short-Term Debt Ascentage Pharma|Quick Ratio ascentage.com
- net income and valuation multiples indicators:
AAPGV - Company Net Income
Basic company analysis:Ascentage (AAPGV)
Core merchandise of Ascentage Pharma

Investors often overestimate the potential of biotechnology, ignoring the colossal expenditures of Ascentage Pharma Group (AAPGV) on international R&D and clinical trials for anti-tumor agents. By analyzing the company's balance sheet profit, you can see the daily net income, which allows for the identification of historical yield extremes and an assessment of the business's real margin of safety amid high dependence on patent protection and regulatory risks.

Direct competitors

Net Income BeiGene Oncology|HALO (Halozyme Therapeutics) - Net Profit|Company Net Income revmed.com RVMD|Company Net Income Ascentage Pharma (AAPG)|CGON (CG Oncology Inc) - Final Profit|UroGen - Net Income|Final Profit BCAX|Personalis, Inc. - Net Profit|erasca.com (ERAS) - Net Income|DCTH (Delcath Systems) - Net Income|Y-mAbs Therapeutics Inc (YMAB) - Net Profit|Company Net Income Aura Bio|CADL: Final Profit|Net Profit ARAY|SLS - Company Net Income|Net Profit ACTU (Actuate Therapeutics)|Net Profit Citius Oncology Inc. CTOR|HURA - Company Net Income|Net Financial Result Protara Tx TARA|FATE: Net Profit|Net Income Aadi Bioscience|TCRX (TScan Therapeutics Inc) - Net Profit|Company Net Income Champions Oncology Corp CSBR|Company Net Income XBiotech Inc. (XBIT)|cel-sci.com - Company Profit|OS Therapies Incorporated - Net Income|Profit After Payment of Taxes RADX (Radiopharm Theranostics Ltd)|Artiva - Net Profit|ANL - Net Profit|VERU: Net Profit|Annual Net Income Tempest Therapeutics Corp TPST|XLO (Xilio Therapeutics Inc) - Net Profit|Company Net Income Enochian BioSciences RENB|Net Income MURA (Mural Oncology plc)|KAPA (kairospharma.com) - Final Profit|Company Net Income OnKure Therapeutics OKUR|GDTC (CytoMed Therapeutics Ltd) - Profit After Tax|Curis Corp - Net Profit|Final Profit APLM (Apollomics, Inc.)|THAR: Net Profit|Advanced Biomed (ADVB) - Net Profit|Company Net Income Genprex, Inc|CLDI: Final Profit|Company Net Income Sunshine Biopharma (SBFM)|Net Income xeneticbio.com XBIO|Net Profit SLRX (Salarius Pharmaceuticals, Inc.)|Net Profit Purple Biotech Ltd PPBT|AONC: Net Income|Final Profit BGNE (BeiGene Ltd)|CKPT: Net Profit|Annual Net Income Elevation Oncology Inc. ELEV|Company Net Income iCAD Inc.|IKNA: Final Profit|Company Net Income Notable Labs Inc. (NTBL)|VIRX - Company Net Income|MorphoSys AG - Net Income|Net Profit nayabiosciences.com NAYA